Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

WALTHAM, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from a real-world analysis being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting showing that gastrointestinal-related healthcare resource utilization (GI-HCRU) dropped significantly after adults with irritable bowel syndrome with constipation (IBS-C) started IBSRELA® (tenapanor). Ardelyx will also present data on how IBS-C symptom burden affects quality of life, along with the design and rationale of an ongoing Phase 3 study evaluating tenapanor in adults with chronic idiopathic constipation (CIC).

"IBS-C can affect patients in ways that extend well beyond their symptoms, placing a significant burden on daily life and quality of life, including through ongoing interactions with the healthcare system. We are encouraged by these real-world findings, which show a significant reduction in GI-related healthcare utilization following IBSRELA initiation," said Rajani Dinavahi, MD, Chief Medical Officer of Ardelyx. "Together with our additional data presented at ACG, these findings reflect our commitment to generating evidence that deepens our understanding of constipation-related disorders, helps inform patient care, and supports continued research into the potential role of tenapanor beyond IBS-C."